Abstract: A method of detecting urine and/or feces is disclosed, which includes detecting the concentration of at least one gas component indicative of urine and the concentration of at least one gas component indicative of feces. The method also includes registering, for each gas component, a characteristic corresponding to the variation over time of the concentration of each gas component; comparing the registered characteristic with a predetermined characteristic for the corresponding gas component; indicating a presence of urine if the registered characteristic of at least one gas component indicative of urine generally conforms with the predetermined characteristic of the same gas component; and indicating a presence of feces if the registered characteristic of at least one gas component indicative of feces generally conforms to the predetermined characteristic of the same gas component. A system for detecting urine and/or feces is also disclosed.

Abstract: The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising iloprost.

Abstract: The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising adrenaline and citric acid showing improved storage stability.

Abstract: The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.

Abstract: The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

Abstract: The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.

Abstract: The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising adrenaline and citric acid showing improved storage stability.

Abstract: A method of detecting urine and/or feces is disclosed, which includes detecting the concentration of at least one gas component indicative of urine and the concentration of at least one gas component indicative of feces. The method also includes registering, for each gas component, a characteristic corresponding to the variation over time of the concentration of each gas component; comparing the registered characteristic with a predetermined characteristic for the corresponding gas component; indicating a presence of urine if the registered characteristic of at least one gas component indicative of urine generally conforms with the predetermined characteristic of the same gas component; and indicating a presence of feces if the registered characteristic of at least one gas component indicative of feces generally conforms to the predetermined characteristic of the same gas component. A system for detecting urine and/or feces is also disclosed.

Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.

Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.

Abstract: The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and/or no-reflow phenomena and/or ischemia-reperfusion injury by administration of agent(s) modulating and/or preserving endothelial integrity.

Abstract: The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

Abstract: The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.